"VSports app下载" Comparative study of lung cancer care and survival outcomes across the Nordic countries
DOI:
https://doi.org/10.2340/1651-226X.2025.42778"VSports手机版" Keywords:
Lung cancer, care practices, treatment outcomes, survival rate, Nordic countriesV体育平台登录 - Abstract
Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide VSports. Despite societal, economic and genetic similarities, 5-year age-standardized relative survival rate is lower in Finland compared to the other Nordic countries. Previous studies have identified discrepancies in LC guidelines, but research on actual care practices remains limited. We aim to address this knowledge gap by conducting a comprehensive examination of the current care practices for LC patients in the Nordic countries.
Methods: We employed a non-interventional, prospective study design. We conducted an expert workshop involving LC specialists from Finland to formulate relevant questions for a structured survey VSports app下载. This survey was distributed to healthcare professionals (HCPs) across Nordic hospitals and primary care units. The survey results were then analyzed, and a follow-up Nordic LC expert workshop was held to identify the most relevant factors potentially influencing LC survival outcomes.
Results: Four key differences in care practices between Finland and other Nordic countries were identified: (1) resources available in primary care units, (2) waiting times in primary care, (3) availability of novel treatments and (4) tracking of LC survival and mortality outcomes by the hospital V体育官网. Finland has the lowest access to computed tomography (CT) from primary care, longest waiting times in primary care, and lacks a national outcome tracking system. Some medical doctors in Finland and Iceland highlighted observed limitations in specific cases involving access to neoadjuvant immunotherapy and chemotherapy.
Interpretation: Several factors unrelated to specialized LC care are likely contributing to poorer 5-year survival rates for LC in Finland VSports手机版. These findings may be applicable to other healthcare systems as well.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin V体育安卓版. 2021;71(3):209–49. .
https://doi. org/10. 3322/caac. 21660 DOI: https://doi V体育ios版. org/10. 3322/caac. 21660 .
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries VSports最新版本. Lancet. 2018 Mar;391(10125):1023–75. .
https://doi. org/10. 1016/s0140-6736(17)33326-3 DOI: https://doi. org/10 V体育平台登录. 1016/S0140-6736(17)33326-3 .
Tichanek F, Försti A, Hemminki O, Hemminki A, Hemminki K. Survival in lung cancer in the Nordic countries through a half century. Clin Epidemiol VSports注册入口. 2023;15:503–10. .
https://doi. org/10. 2147/CLEP. S406606 DOI: https://doi. org/10. 2147/CLEP V体育官网入口. S406606 .
Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic Health Registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533–54.
https://doi.org/10.2147/CLEP.S314959 DOI: https://doi.org/10.2147/CLEP.S314959
Hemminki J, Försti A, Hemminki A, Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022;175:77–85.
https://doi.org/10.1016/j.ejca.2022.08.015 DOI: https://doi.org/10.1016/j.ejca.2022.08.015
Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax. 2013;68(6):551–64.
https://doi.org/10.1136/thoraxjnl-2012-202297 DOI: https://doi.org/10.1136/thoraxjnl-2012-202297
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
https://doi.org/10.1016/j.jtho.2015.09.009 DOI: https://doi.org/10.1016/j.jtho.2015.09.009
He S, Li H, Cao M, Sun D, Yang F, Yan X, et al. Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. Transl Lung Cancer Res. 2022 Aug;11(8):1591–605.
https://doi.org/10.21037/tlcr-22-240 DOI: https://doi.org/10.21037/tlcr-22-240
Hu X, Chirovsky D, Walker MS, Wang Y, Kaushiva A, Tepsick J, et al. A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection. BMC Pulm Med. 2024 Jul 10;24(1):332.
https://doi.org/10.1186/s12890-024-03138-y DOI: https://doi.org/10.1186/s12890-024-03138-y
Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 2010 Oct;21:vii196–8.
https://doi.org/10.1093/annonc/mdq376 DOI: https://doi.org/10.1093/annonc/mdq376
Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001 Mar;31(2–3):139–48. DOI: https://doi.org/10.1016/S0169-5002(00)00181-1
https://doi.org/10.1016/s0169-5002(98)00068-3 DOI: https://doi.org/10.1016/S0169-5002(98)00068-3
NORDCAN. Association of the Nordic Cancer Registries [Internet]. 2025 [cited 2024 Mar 11]. Available from: https://nordcan.iarc.fr/en
Sehgal K, Gill RR, Widick P, Bindal P, Mcdonald DC, Shea M, et al. Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw Open. 2021;4(2):e2037120.
https://doi.org/10.1001/jamanetworkopen.2020.37120 DOI: https://doi.org/10.1001/jamanetworkopen.2020.37120
Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TÅ, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019 Nov;20(11):1493–505.
https://doi.org/10.1016/S1470-2045(19)30456-5 DOI: https://doi.org/10.1016/S1470-2045(19)30456-5
Leskelä RL, Peltonen E, Haavisto I, Herse F, Korhonen S, Nolvi K, et al. Trends in treatment of non-small cell lung cancer in Finland 2014–2019. Acta Oncol. 2022 May 4;61(5):641–8.
https://doi.org/10.1080/0284186X.2022.2042474 DOI: https://doi.org/10.1080/0284186X.2022.2042474
The Swedish National Lung Cancer Register [Internet]. [cited 2024 Mar 11] Available from: https://cancercentrum.se/globalassets/cancerdiagnoser/lunga-och-lungsack/kvalitetsregister/rapport/20241105_nlcr_nationell_rapport2023.pdf
Gouliaev A, Berg J, Khalil AA, Dalton SO, Rasmussen TR, Christensen NL. Factors behind favorable long-term lung cancer survival in Norway compared to Denmark: a retrospective cohort study. Eur Clin Respir J. 2024 Dec 31;11(1):2414485.
https://doi.org/10.1080/20018525.2024.2414485 DOI: https://doi.org/10.1080/20018525.2024.2414485
Löfling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Temporal trends in lung cancer survival: a population-based study. Acta Oncol. 2022;61(5):625–31.
https://doi.org/10.1080/0284186X.2021.2013529 DOI: https://doi.org/10.1080/0284186X.2021.2013529
Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Møller B. Lung cancer survival in Norway, 1997–2011: from nihilism to optimism. Eur Respir J. 2016;47(1):275–87.
https://doi.org/10.1183/13993003.00650-2015 DOI: https://doi.org/10.1183/13993003.00650-2015
Makitaro R, Paakko P, Huhti E, Bloigu R, Kinnula V. An epidemiological study of lung cancer: history and histological types in a general population in northern Finland. Eur Respir J. 1999;13(2):436–40. DOI: https://doi.org/10.1034/j.1399-3003.1999.13b36.x
https://doi.org/10.1183/09031936.99.13243699 DOI: https://doi.org/10.1183/09031936.99.13243699
Pukkala E, Engholm G, Højsgaard Schmidt LK, Storm H, Khan S, Lambe M, et al. Nordic Cancer Registries – an overview of their procedures and data comparability. Acta Oncol. 2018;57(4):440–55.
https://doi.org/10.1080/0284186X.2017.1407039 DOI: https://doi.org/10.1080/0284186X.2017.1407039
Gouliaev A, Rasmussen TR, Malila N, Fjellbirkeland L, Löfling L, Jakobsen E, et al. Lung cancer registries in Denmark, Finland, Norway and Sweden: a comparison and proposal for harmonization. Acta Oncol. 2023 Jan 2;62(1):1–7.
https://doi.org/10.1080/0284186X.2023.2172687 DOI: https://doi.org/10.1080/0284186X.2023.2172687
Lynch C, Harrison S, Butler J, Baldwin DR, Dawkins P, Van Der Horst J, et al. An International consensus on actions to improve lung cancer survival: a modified Delphi method among clinical experts in the international cancer benchmarking partnership. Cancer Control. 2022 Jan;29:107327482211193.
https://doi.org/10.1177/10732748221119354 DOI: https://doi.org/10.1177/10732748221119354
Christensen NL, Jekunen A, Heinonen S, Dalton SO, Rasmussen TR. Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncol. 2017 Jul 3;56(7):943–8.
https://doi.org/10.1080/0284186x.2017.1315172 DOI: https://doi.org/10.1080/0284186X.2017.1315172
Coleman M, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–38.
https://doi.org/10.1016/S0140-6736(10)62231-3 DOI: https://doi.org/10.1016/S0140-6736(10)62231-3
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
https://doi.org/10.3322/caac.21492 DOI: https://doi.org/10.3322/caac.21492
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208.
https://doi.org/10.1016/j.jbi.2019.103208 DOI: https://doi.org/10.1016/j.jbi.2019.103208
Sone S, Takashima S, Li F, Yang Z, Honda T, Maruyama Y, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998 Apr;351(9111):1242–5.
https://doi.org/10.1016/S0140-6736(97)08229-9 DOI: https://doi.org/10.1016/S0140-6736(97)08229-9
Computed tomography (CT) scanners [Internet]. OECD. [cited 2024 Dec 12]. Available from: https://www.oecd.org/en/data/indicators/computed-tomography-ct-scanners.html
De Koning HJ, Van Der Aalst CM, De Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–13.
https://doi.org/10.1056/NEJMoa1911793 DOI: https://doi.org/10.1056/NEJMoa1911793
Finnish Institute for Health and Welfare. Avohilmo: perusterveydenhuollon hoitoonpääsyn 14 vuorokauden enimmäisajan toteutuminen [Internet]. 2024 [cited 2024 May 25]. Available from: https://sampo.thl.fi/pivot/prod/fi/avohpaasy/pthjono01/fact_ahil_pthjono01?row=palveluntuottaja-26624&column=odotusaika-25575&filter=measure-486013&filter=ammatti-110048&filter=palvelumuoto-121032&filter=aika-835338#
Walter FM, Rubin G, Bankhead C, Morris HC, Hall N, Mills K, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer. 2015 Mar 31;112(Suppl 1):S6–13.
https://doi.org/10.1038/bjc.2015.30 DOI: https://doi.org/10.1038/bjc.2015.30
Car LT, Papachristou N, Bull A, Majeed A, Gallagher J, El-Khatib M, et al. Clinician-identified problems and solutions for delayed diagnosis in primary care: a PRIORITIZE study. BMC Fam Pract. 2016;17(1):131.
https://doi.org/10.1186/s12875-016-0530-z DOI: https://doi.org/10.1186/s12875-016-0530-z
Vedsted P, Olesen F. Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. Br J Gen Pract. 2011;61(589):e508–12.
https://doi.org/10.3399/bjgp11X588484 DOI: https://doi.org/10.3399/bjgp11X588484
Annakkaya AN, Arbak P, Balbay O, Bilgin C, Erbas M, Bulut I. Effect of symptom-to-treatment interval on prognosis in lung cancer. Tumori. 2007;93(1):61–7.
https://doi.org/10.1177/030089160709300111 DOI: https://doi.org/10.1177/030089160709300111
Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Ståhle E. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax. 2004 Jan;59(1):45–9.
Neal RD, Din NU, Hamilton W, Ukoumunne OC, Carter B, Stapley S, et al. Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database. Br J Cancer. 2014;110(3):584–92.
https://doi.org/10.1038/bjc.2013.791 DOI: https://doi.org/10.1038/bjc.2013.791
Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, et al. Time to initial cancer treatment in the United States and association with survival over time: an observational study. Ahmad A, editor. PLoS One. 2019 Mar;14(3):e0213209. DOI: https://doi.org/10.1371/journal.pone.0213209
journal.pone.0213209
O’Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol. 2000 Jun;12(3):141–4.
https://doi.org/10.1053/clon.2000.9139 DOI: https://doi.org/10.1053/clon.2000.9139
Cancer IO. Cancer Immunotherapies in Finland [Internet]. Cancer IO; 2022 [cited 2024 Mar 18]. Available from: https://cancerio.org/en/cancer-immunotherapies-in-finland/
Bhati D, Deogade MS, Kanyal D. Improving patient outcomes through effective hospital administration: a comprehensive review. Cureus. 2023;15(10):e47731.
https://doi.org/10.7759/cureus.47731 DOI: https://doi.org/10.7759/cureus.47731
"VSports" Additional Files
Published
How to Cite
Issue
V体育ios版 - Section
Categories
License
Copyright (c) 2025 Ghida Khalife, Juho Waris, Uffe Bødtger, Johan Isaksson, Kirill Neumann, Hrönn Harðardóttir, Heidi Andersén, Antti Jekunen, Maria Lovén, Tuula Vasankari, Susanna Nurmi-Rantala, Paulus Torkki
This work is licensed under a Creative Commons Attribution 4.0 International License.
